ClinicalTrials.gg
CompletedNCT00632125EPO-PASSUpdated Jul 11, 2017Results posted

Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.

A Phase 4 interventional study of HX575 recombinant human erythropoietin alfa in Chronic Kidney Disease, sponsored by Sandoz. Completed at 114 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-11.

Sponsored by Sandoz (formerly part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,695
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic — 1 open to participants now, 1 under way, none of them phase 3. Epoetin Alfa · Renal Insufficiency, Chronic.

Enrollment
Largest of 25
1,695 · median 157
Started
2008
the only one that year
Phase 4
7 of 25
none open now
Registered
10th of 25
by date
Lead sponsor
4 of 25
Sandoz

Among the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, this one has the largest enrollment, is the only one that started in 2008, is one of 7 in phase 4, and was the 10th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

1 of the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

Cumulative follow-up with HX575 epoetin alfa to prospectively monitor the incidence of relevant drug-related adverse events and EPO-related lack of efficacy among Chronic Kidney Disease (CKD) subjects receiving HX575 epoetin alfa i.v.

Read the detailed description

This study was a multi-center, multinational, prospective, single-arm clinical study with a 6-month treatment period. The primary objective was to extend the safety database of patients with CKD who receive i.v. HX575 epoetin alfa treatment and to monitor the adverse event (AE) profile under post-approval conditions.

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • CKD subjects with or without dialysis treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CKD subjects with or without dialysis treatment
  • Age over 18 years
  • Subjects requiring i.v. ESA treatment
  • Subjects likely to remain on i.v. ESA treatment for 6 months
  • Provision of -

Exclusion criteria

Exclusion Criteria:

  • Systemic medication or any other drugs known to adversely affect the level
  • Known primary lack of efficacy (LOE), unexplained loss of effect to a recombinant erythropoietin product
  • History of PRCA or aplastic anemia
  • History of anti-erythropoietin antibodies
  • Uncontrolled hypertension
  • Pregnant woman or nursing mother
  • Women of do not agree to maintain effective during the study treatment period.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,695 participants (actual)

Study arms

  • Experimental
    HX575 epoetin alfa i.v.

    This post-authorization safety study was designed as a multi-center, multinational, prospective, single-arm clinical study with a 6-month HX575 (recombinant human) erythropoietin alfa treatment period. It was planned to include approximately 1,500 patients.

    Drug: HX575 recombinant human erythropoietin alfa

Interventions

06

What researchers measure

Primary outcomes

  1. Drug-related Adverse Events Consisting of Epoetin Alfa-induced Immunogenicity and Resulting Clinical Effects

    The incidence of relevant drug-related adverse events consisting of Epoetin alfa-induced immunogenicity and resulting blockade in erythroid maturation (e.g. pure red cell aplasia) and lack of efficacy

    Time frame: 6 months

07

Results

Posted Jul 11, 2017

Participant flow

Participant flow — Overall Study
MilestoneHX575
Started1695
Completed1393
Not completed302
Withdrew: Death82
Withdrew: Withdrawal by subject44
Withdrew: Adverse event36
Withdrew: Renal transplantation17
Withdrew: Need for systemic immunosuppressive medi8
Withdrew: Non-compliance8
Withdrew: Development of uncontrolled hypertension5
Withdrew: Moved to other dialysis unit, etc.102

Outcome measures

PrimaryDrug-related Adverse Events Consisting of Epoetin Alfa-induced Immunogenicity and Resulting Clinical Effects

The incidence of relevant drug-related adverse events consisting of Epoetin alfa-induced immunogenicity and resulting blockade in erythroid maturation (e.g. pure red cell aplasia) and lack of efficacy

Time frame:
6 months
Reported as:
Number · percentage of participants
Drug-related Adverse Events Consisting of Epoetin Alfa-induced Immunogenicity and Resulting Clinical Effects
percentage of participantsHX575
Drug-related AEs7 (5.9 to 8.3)
EPO-related lack of efficacy events0.18 (0.04 to 0.52)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HX57582/1,695 (4.8%)456/1,695 (26.9%)1,314/1,695 (77.5%)
Most frequent serious events
Showing 10 of 368
Most frequent serious events
EventHX575
PneumoniaInfections and infestations34/1695
Arteriovenous fistula thrombosisInjury, poisoning and procedural complications24/1695
Shunt thrombosisInjury, poisoning and procedural complications17/1695
SepsisInfections and infestations16/1695
Atrial fibrillationCardiac disorders13/1695
Gastrointestinal haemorrhageGastrointestinal disorders11/1695
Peripheral arterial occlusive diseaseVascular disorders11/1695
Arteriovenous fistula site complicationInjury, poisoning and procedural complications11/1695
Cardiac failureCardiac disorders11/1695
Cardiac arrestCardiac disorders10/1695
Most frequent other events
Most frequent other events
EventHX575
Muscle spasmsMusculoskeletal and connective tissue disorders223/1695
HeadacheNervous system disorders181/1695
HypertensionVascular disorders174/1695
DiarrhoeaGastrointestinal disorders161/1695
HypotensionVascular disorders145/1695
BronchitisInfections and infestations136/1695
Procedural hypotensionInjury, poisoning and procedural complications111/1695
NauseaGastrointestinal disorders105/1695
VomitingGastrointestinal disorders102/1695
NasopharyngitisInfections and infestations100/1695

Baseline characteristics

Age, Continuous
Age, Continuous(years)HX575
Mean61.8 ± 15.4
Sex: Female, Male
Sex: Female, Male(Participants)HX575
Female737
Male958
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HX575
American Indian or Alaska Native0
Asian9
Native Hawaiian or Other Pacific Islander0
Black or African American6
White1671
More than one race0
Unknown or Not Reported9
Region of Enrollment
Region of Enrollment(participants)HX575
Austria44
Russian Federation29
Romania103
Macedonia, The Former Yugoslav Republic of143
Ukraine204
Poland220
Italy205
Bulgaria45
France1
Germany701
08

Study locations

114 sites
  • Dialysepraxis Dres. Huspek/Schmid
    Bad Ischl, 4820, Austria
  • Landeskrankenhaus Feldkirch
    Feldkirch, 6800, Austria
  • Landeskrankenhaus Freistadt
    Freistadt, 4240, Austria
  • LKH Rohrbach
    Rohrbach, 4150, Austria
  • Universitätsklinik für Innere Medizin III
    Wien, 1090, Austria
  • Multiprofile Hospital for Active Treatment Dr. Tota Venkova
    Gabrovo, 5300, Bulgaria
  • Multiprofile Hospital for Active Treatment Dr. Kiro Popov
    Karlovo, 4300, Bulgaria
  • Multiprofile Hospital for Active Treatment Pazardzhik
    Pazardzhik, 40400, Bulgaria
  • Multiprofile Hospital for Active Treatment Rousse
    Rousse, 7002, Bulgaria
  • Multiprofile Hospital for Active Treatment Sv. Ivan Rilski
    Sofia, 1431, Bulgaria
  • Ministry of Interior-Central Clinical Base
    Sofia, 1606, Bulgaria
  • CHG Hopital Yves le Foll
    St Brieuc, 22023, France
  • Fachpraxis für Nieren und Hochdruckerkrankungen
    Andernach, 56626, Germany
  • KfH Kuratorium für Nierentranplantation und Dialyse e.V.
    Aschaffenburg, 63741, Germany
  • Gemeinschaftspraxis
    Baunatal, 34225, Germany
  • Kuratorium ür Dialyse und Nierentransplantation e.V.
    Bayreuth, 95445, Germany
  • KfH Nierenzentrum
    Berlin, 12247, Germany
  • Alwall Praxis für Nieren- und Hochdruckkrankheiten
    Berlin, 13125, Germany
  • Dialysepraxis
    Bremerhaven, 27570, Germany
  • Dialysepraxis Drs. Riedasch/Schreiber
    Coesfeld, 48653, Germany
  • Facharzt für Innere Medizin und Nephrologie, Dialyse Centrum
    Darmstadt, 64295, Germany
  • KfH Kuratorium für Nierentranplantation und Dialyse e.V.
    Deggendorf, 94469, Germany
  • Dialysezentrum
    Dinkelsbühl, 91550, Germany
  • Diabetes- und Dialysezentrum Merker, Vogt
    Dormagen, 41539, Germany
  • KfH Nierenzentrum
    Dortmund, 44141, Germany
  • Gemeinschaftspraxis Karlstraße
    Düsseldorf, 40210, Germany
  • Kuratorium für Dialyse und Nierentransplantation e.V.
    Ehingen, 89584, Germany
  • Dialysezentrum Elsenfeld
    Elsenfeld, 63820, Germany
  • Gemeinschaftspraxis Dr. Spitthöver, Dr. Knee, Dr. Gröschel
    Essen, 45127, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V.
    Essen, 45136, Germany
  • Dialysezentrum
    Freiburg, 79110, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Fürstenzell, 94081, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Gummersbach, 51643, Germany
  • Dialyse Hamburg Barmbek
    Hamburg, 22297, Germany
  • Dialysepraxis Dr. Spengler
    Helmstedt, 38350, Germany
  • Marienhospital Herne
    Herne, 44625, Germany
  • Dialyse-Zentrum Elsterland
    Herzberg, 04916, Germany
  • Praxis Dr. Menzer
    Homberg/Efze, 34576, Germany
  • Nephrologische Praxis
    Höchstadt, 91315, Germany
  • Gemeinschaftspraxis
    Kamp-Lintfort, 47475, Germany
  • KfH Nierenzentrum
    Köln, 50937, Germany
  • Dialysepraxis
    Lahr, 77933, Germany
  • Praxis für Innere Medizin und Nephrologie
    Leverkusen, 51373, Germany
  • Nephrologisches Zentrum Emsland
    Lingen, 49808, Germany
  • Dialysezentrum und Schwerpunktpraxis für Nieren- und Hochdruckerkrankungen
    Mannheim, 68309, Germany
  • Gemeinschaftspraxis
    Mayen, 56727, Germany
  • Nephrologisches Zentrum Mettmann
    Mettmann, 40822, Germany
  • KfH Kuratorium für Nierentranplantation und Dialyse e.V.
    Oberschleißheim, 85764, Germany
  • Nierenzentrum Prenzlau
    Prenzlau, 17291, Germany
  • Nephrologische Ambulanz/ Dialyse
    Singen, 78224, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.V
    Straubing, 94315, Germany
  • Nieren- und Diabeteszentrum Viersen-Nettetal
    Viersen-Dülken, 41751, Germany
  • IRCCS INRCA Sede de Ancona
    Ancona, 60100, Italy
  • Ospedali Riuniti di Anzio e Nettuno
    Anzio, 00042, Italy
  • U.O.C. Nefrologia e Dialisi, C.G. Mazzoni
    Ascoli Piceno, 63100, Italy
  • Ospedaliero Universitaria Policlinico S. Orsola Malpighi
    Bologna, 40138, Italy
  • Azienda Ospdealiero "Istituti Ospitalieri"
    Cremona, 26100, Italy
  • Ospedale E. Profili di Fabriano
    Fabriano, 60044, Italy
  • AO Universitaria Ospedali Riuniti
    Foggia, 71100, Italy
  • Universitaria Degli Studi di Genova Clinica Nefrologica, Dialisi e Trapianto
    Genova, 16132, Italy
  • Ospedale A. Manzoni
    Lecco, 23900, Italy
  • Azienda Ospedaliera Carlo Poma di Mantova
    Mantova, 46100, Italy
  • Azienda Ospedaliera Ospedale San Carlo Borromeo
    Milano, 20153, Italy
  • Azienda Ospedaliera Ospedale Niguarda Ca Granda
    Milano, 20162, Italy
  • AO Universitaria di Modena
    Modena, 41100, Italy
  • Ospedale Maggiore di Modica
    Modica, 97015, Italy
  • U.O. Nefrologia e Dialisi, P.O. Ospedale Casati, Centro Dialisi
    Passirana di Rho, 20017, Italy
  • Fondazione S. Maugeri
    Pavia, 27100, Italy
  • Azienda Ospedaliera ospedale S. Salvatore
    Pesaro, 61100, Italy
  • Ospedale A. Landolfi
    Solofra, 83029, Italy
  • Azienda Ospedaliera CTO - Maria Adelaide
    Torino, 10126, Italy
  • Ospedale San Giovanni Bosco
    Torino, 10154, Italy
  • Ospedale di Trento / Santa Chiara
    Trento, 38100, Italy
  • Ospedale dell'Angelo
    Venezia Mestre, 30173, Italy
  • PHO Clinical Hospital Dr. Trifun Panovski
    Bitola, 7000, Macedonia, The Former Yugoslav Republic of
  • PHO Health organisation Goce Delcev
    Delcevo, 2320, Macedonia, The Former Yugoslav Republic of
  • PHO General Hospital Kocani
    Kocani, 2300, Macedonia, The Former Yugoslav Republic of
  • PHO General Hospital Borka Taleski
    Prilep, 7500, Macedonia, The Former Yugoslav Republic of
  • PHO Clinic of Nephrology
    Skopje, 1000, Macedonia, The Former Yugoslav Republic of
  • PHO General Hospital Stip
    Stip, 1000, Macedonia, The Former Yugoslav Republic of
  • Institute of Nephrology
    Struga, 6330, Macedonia, The Former Yugoslav Republic of
  • PHO Medical Center Veles
    Veles, 1400, Macedonia, The Former Yugoslav Republic of
  • Specjalistyczny Szpital Wojewodzki w Ciechanowie
    Ciechanow, 06-400, Poland
  • Wojewodzki Szpital Specjalistyczny im. Najswietszej maryi Panny
    Czestochowa, 42-200, Poland
  • Samodzielnym Publicznym Zakladzie Opieki Zdrowotnej Dzialdowo
    Dzialdowo, 13-200, Poland
  • Stacja Dializ w Garwolinie
    Garwolin, 08-400, Poland
  • Szpital Specjalistyczny Sw. W. Adalberta
    Gdansk, 80-462, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej AVITUM
    Golub-Dobrzyn, 87-400, Poland
  • B. Braun AVITUM Poland Sp.
    Legnica, 59-220, Poland
  • SP Szpital Kliniczny im. Barlickiego
    Lodz, 90-153, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 4
    Lublin, 20-954, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej
    Pabianice, 95-200, Poland
  • Radomski Szpital Specjalistyszny im. Dr Tytusa Chalubinskiego
    Radom, 26-610, Poland
  • Wojewodzki Szpital Specjalistyczny nr 3
    Rybnik, 44-200, Poland
  • Szpital Powiatowy im. Lekarza Z. Koprowskiego
    Warsaw, 08-300, Poland
  • Szpital Bielanski Blok F
    Warszawa, 01-809, Poland
  • Centralny Szpital Kliniczny MSWiA
    Warszawa, 02-507, Poland
  • Spitalul Clinic Municipal
    Arad, 310017, Romania
  • Institutul Clinic Fundeni
    Bucharest, 022328, Romania
  • Spitalul Clinic de urgenta "Floreasca"
    Bucharest, 14461, Romania

Showing the first 100 of 114 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Horl WH, Locatelli F, Haag-Weber M, Ode M, Roth K; Epo-PASS study group. Prospective multicenter study of HX575 (biosimilar epoetin-alpha) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl. Clin Nephrol. 2012 Jul;78(1):24-32. doi: 10.5414/cn107440. PubMed 22732334 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Mar 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 7 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2008
First posted
Mar 10, 2008
Start
Jul 2008
Primary completionActual
Mar 2010
CompletionActual
Sep 2010
Results first posted
Jul 11, 2017
Last update
Jul 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00632125
Lead sponsor
Sandoz
Collaborators
Hexal AG
Responsible party
Sponsor
First posted
Mar 10, 2008
Start date
Jul 2008
Primary completion
Mar 2010
Completion
Sep 2010
Results posted
Jul 11, 2017
Last update
Jul 11, 2017

Study contacts

Karsten Roth, Dr
study chair · Hexal AG

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion